Chad Landmon chairs Polsinelli’s Hatch-Waxman & Biologics Practice and is a first chair trial lawyer known for his adept handling of patent litigation, the Food and Drug Administration (FDA) approval processes, and Administrative Procedure Act (APA) litigation, ensuring clients can efficiently and profitably bring their products to market.

He is recognized globally as a leading patent litigator by IAM Patent 1000, Benchmark Litigation, and Law360, and has successfully litigated over 60 cases in the past decade alone. His notable achievements include leading a groundbreaking case in which a court mandated the FDA to approve a product—a benchmark case covered extensively by the media. Recognized as a "Life Sciences Star" by LMG Life Sciences and a "Health Care/Life Sciences Trailblazer" by The National Law Journal, Chad has advised on nine of the top 10 generic drugs by cost savings and nearly half of the top 100 by sales volume.

Chad's practice uniquely combines his litigation experience with a deep understanding of navigating the complex FDA regulatory landscape and the unique issues that arise in challenging government agencies in APA litigation. He serves as first chair trial counsel in patent disputes while also handling FDA citizen petitions and APA litigation involving marketing exclusivities, patent listings, bioequivalence, labeling and other critical FDA approval issues, along with issues that arise in the health care industry. He works with clients spanning pharmaceuticals, biologics, medical devices, and human tissue products with billions of dollars in annual sales.

Beyond his primary focus, Chad manages cases involving the cross-section of antitrust and patent law, particularly those arising from settlements of patent disputes and Hatch-Waxman Act exclusivity disputes. His experience extends to navigating challenges posed by the Biologics Price Competition and Innovation Act and other litigation impacting the life sciences and health care industries.

Chad frequently speaks and writes about an array of issues relating to litigation in the life sciences industry, including skinny label litigation, the U.S. regulatory landscape generally, and issued relating to cell and gene therapies. He was active in local government in Southbury, Connecticut, for nearly a decade, including serving as an elected member of their Board of Selectmen. Additionally, Chad is a strong supporter of charity: water, a nonprofit that brings clean water to communities around the world.